Cost-effectiveness research on preventive interventions: a survey of the publications in 2008.
BACKGROUND
In recent years the literature regarding the cost-effectiveness of disease prevention and health promotion has grown exponentially. Aim of this study is to investigate: (i) how many and what type of economic evaluations have been published in 2008, (ii) the diseases or health problems World Health Organization International Classification of Diseases 10 chapters the economic evaluations of preventive interventions focus on, in relation to the global burden of disease and (iii) the cost-effectiveness of these interventions.


METHODS
Literature study of economic evaluations on preventive interventions in PubMed and Scopus.


RESULTS
In 2008, 232 economic evaluations of preventive interventions have been published. Of these studies, 75% (n = 175) used costs per (Quality Adjusted) Life Year [(QA)LY] gained as outcome measure. Most economic evaluations focus on the prevention of infectious diseases (31.5%, n = 73) and cancers (21%, n = 49) Infectious diseases are responsible for the highest global burden of disease (19.8%), followed by mental and behavioural disorders (11.7%). Of the included economic evaluations, 80% remained below a threshold of €50 000 and 60% below €20 000 per (QA)LY.


CONCLUSIONS
This study shows that many economic evaluations of preventive interventions use a generic outcome measure. This adds to the comparability of different studies on the cost-effectiveness of prevention. Although the focus of published economic evaluations in general corresponds well with those diseases that cause a large share of the world's burden of disease, mental and behavioural diseases and diseases of the respiratory system remain underrepresented. Finally, it appears that the vast majority of published economic evaluations of preventive measures show favourable cost-effectiveness levels.
National Institute for Public Health and the Environment, Centre for Prevention and Health Services Research, Bilthoven, The Netherlands. paul.van.gils@rivm.nl
Paul F
PF
van Gils
Luqman
L
Tariq
Marieke
M
Verschuuren
Matthijs
M
van den Berg
D003140:Communicable Disease Control / Q000191:economics; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006293:Health Promotion / Q000191:economics*; D006801:Humans; D011322:Primary Prevention / Q000191:economics*; D039781:PubMed; D019057:Quality-Adjusted Life Years; D012106:Research; D012196:Review Literature as Topic; D014944:World Health Organization